Earth logo

North America Heart Pump Device Market Size & Forecast 2025–2033

Advanced Cardiac Care, Aging Populations, and Next-Gen Medical Technology Push Heart Pump Devices Into a New Era of Growth

By Sushant. Renub ResearchPublished 2 months ago 6 min read

The North America Heart Pump Device Market is gearing up for a decade of strong expansion, rising from US$ 2.92 billion in 2024 to US$ 8.1 billion by 2033, according to forecast estimates. This robust upward trajectory reflects a healthy 12% CAGR between 2025 and 2033, driven by escalating cardiovascular disease cases, technological innovation, and a rapidly aging population. With advanced cardiac care becoming increasingly essential, heart pump devices—once considered niche, high-risk solutions—are now gaining broad clinical acceptance across hospitals and specialized cardiac centers throughout the region.

These devices, ranging from ventricular assist devices (VADs) to intra-aortic balloon pumps (IABPs) and total artificial hearts, have become indispensable for managing advanced heart failure and life-threatening cardiac complications. As North America continues to grapple with lifestyle-linked diseases and the burden of aging populations, the demand for heart pump solutions continues to expand at an unprecedented pace.

Request Free Sample Report

North America Heart Pump Device Market Outlook

Heart pump devices are mechanical circulatory support systems developed to maintain or improve the pumping function of weakened hearts. They assist in treating patients with severe cardiovascular disease, particularly those with advanced heart failure or those awaiting heart transplantation. In clinical practice across North America, devices such as Left Ventricular Assist Devices (LVADs) and Total Artificial Hearts (TAHs) have become critical to sustaining life in patients with limited treatment options.

Beyond transplant delays and severe cardiac episodes, these devices help patients regain stability, reduce symptoms like dyspnea and fatigue, and improve overall quality of life. Their utility spans high-risk surgical interventions, acute cardiogenic shock cases, and recovery after major cardiac events.

The steady growth in demand for such devices can largely be attributed to technological improvements that enhance the safety and performance of heart pump systems. As more devices become compact, energy-efficient, biocompatible, and capable of remote monitoring, their adoption in both emergency and chronic care settings is accelerating.

Growth Drivers in the North America Heart Pump Device Market

1. Rising Prevalence of Cardiovascular Diseases

North America continues to face a sizable cardiovascular challenge. Heart failure, coronary artery disease, and arrhythmias are prevalent across the U.S. and Canada, often progressing to severe stages that necessitate advanced intervention.

Recent statistics are alarming:

In 2023, the United States recorded 919,032 deaths attributed to cardiovascular conditions—one in every three deaths nationwide.

Canada's 65+ population, a key demographic for heart failure, is projected to rise from 18.5% in 2021 to as high as 29.8% by 2068, according to demographic projections.

Age, in itself, correlates strongly with heart disease. Combined with rising cases of diabetes, obesity, and hypertension, the need for long-term solutions such as VADs and IABPs has become more pressing. This growing patient population is a significant engine behind the market’s expansion.

2. Rapid Technological Innovations in Heart Pump Devices

The heart pump device market is undergoing a technological renaissance. Innovations aimed at miniaturization, wireless power transfer, and improved biocompatibility are making devices more reliable and less prone to complications.

Key advancements include:

Fully implantable VADs

Remote monitoring capabilities

Smarter battery management systems

Improved blood-flow algorithms to reduce thrombosis risks

In December 2024, Johnson & Johnson MedTech secured FDA approval to expand the Impella 5.5 with SmartAssist and Impella CP indications for pediatric patients suffering from acute heart failure or cardiogenic shock. The approval marks a significant leap for mechanical circulatory support access among younger patients—a category previously underserved.

Such innovations not only expand the patient pool but also increase physician confidence in device safety and efficacy, propelling broader adoption throughout the region.

3. Strong Healthcare Infrastructure and Favorable Reimbursement Policies

The well-established healthcare infrastructure in the U.S. and Canada plays a foundational role in the increasing uptake of heart pump devices. Insurance systems in the U.S., including Medicare and Medicaid, cover a broad spectrum of advanced cardiovascular interventions, easing the financial load on patients.

Similarly, Canada’s single-payer universal healthcare system ensures equitable access to essential heart care technologies, including VADs and intra-aortic balloon pumps.

Supportive reimbursement frameworks, coupled with the presence of specialized cardiac centers and expertly trained staff, significantly accelerate device adoption. Regular training, advanced surgical capabilities, and government initiatives to boost cardiac care further promote market growth.

Challenges in the North America Heart Pump Device Market

1. High Cost of Devices and Surgeries

Heart pump devices are expensive—both to purchase and to implant. VAD systems alone can cost tens of thousands of dollars, not including surgery, hospital stays, post-operative drugs, and management of complications.

While insurance coverage helps, not all patients qualify, and high out-of-pocket costs remain a major barrier. Hospitals also face significant investment burdens to procure and maintain these advanced devices. These financial hurdles pose a notable challenge to widespread adoption, especially in lower-income urban or rural populations.

2. Risks and Complications Associated with Devices

Even with ongoing improvements, heart pump devices introduce risks such as:

Blood clots

Infection

Bleeding

Stroke

Mechanical failure

Patients depend on lifelong monitoring and strict medical adherence after implantation. Although complication rates are decreasing, these safety concerns may make clinicians hesitant to recommend devices to certain patient groups, especially those with moderate heart failure who may benefit from less invasive treatments.

Regional Market Landscape

North America Market Overview

North America remains a global hub for heart pump innovation and usage. The region's strong healthcare spending, world-class cardiac centers, and leading medical device companies continue to propel demand. The U.S. is the dominant force in the region, although Canada is steadily increasing adoption owing to its aging population and government-backed care initiatives.

Key devices gaining traction include:

Ventricular Assist Devices (VADs)

Intra-Aortic Balloon Pumps (IABPs)

Total Artificial Hearts

Extracorporeal Membrane Oxygenation (ECMO) pumps

While challenges remain—particularly around cost and long-term complication management—the overall outlook remains positive as technological advances streamline performance and patient outcomes.

Market Segment Insights

1. Ventricular Assist Devices (VADs)

VADs are experiencing the fastest regional growth and are widely used as:

Bridge-to-transplant

Destination therapy

Bridge-to-recovery

The U.S. is the biggest adopter, thanks to strong reimbursement support. Canada is catching up due to government-funded access for advanced heart failure patients. New-generation implantable systems with minimal infection risk and longer durability are helping propel this segment forward.

2. Intra-Aortic Balloon Pumps (IABPs)

IABPs continue to serve a critical role in emergency cardiac care, especially for:

Acute myocardial infarction

Cardiogenic shock

Stabilization prior to transplant or VAD implantation

Despite competition from newer percutaneous heart pumps, IABPs remain favored for their simplicity and lower cost. Adoption remains stable across U.S. and Canadian emergency care units.

3. Implanted Heart Pump Devices

Implanted devices, primarily VADs, dominate long-term therapy for chronic heart failure. The U.S. leads due to wider clinical acceptance and better reimbursement coverage. Technological improvements such as wireless charging and smaller device sizes continue to reduce surgical complexity and patient discomfort.

4. End-Use Markets: Hospitals & Cardiac Centers

Hospitals are the largest end-users, equipped with advanced surgical rooms and intensive care units required for device implantation. Specialty cardiac centers play an expanding role due to their research orientation, clinical trials, and expertise in handling complex cases.

The U.S. maintains leadership thanks to top-tier hospitals and academic medical centers. Canada’s cardiac centers are rapidly advancing, supported by public funding and government-backed healthcare expansion.

Country-Level Analysis

United States Market

The U.S. dominates the regional market due to its advanced healthcare system, high cardiovascular patient load, and rapid adoption of new technologies.

A major development occurred in January 2025, when cardiac surgeons at the University of Michigan implanted a new mechanical heart pump as part of a groundbreaking clinical trial aimed at comparing a new device with the current standard of care for end-stage heart failure.

Such developments reinforce the U.S.’s leadership in heart pump research and deployment.

Canada Market

Canada continues to expand access to advanced cardiac care under its public healthcare system. Rising rates of obesity, aging, and diabetes ensure sustained demand for mechanical circulatory support.

A notable milestone in August 2024 saw Abbott receive FDA approval for a label update on the HeartMate 3 LVAD, removing aspirin from standard therapy protocols—a change also acknowledged in Canada. This marks progress in improving clinical outcomes and reducing bleeding risks for Canadian patients.

Market Segmentations (As Requested)

Product

Ventricular Assist Devices (VADs)

Intra-Aortic Balloon Pumps (IABPs)

Extracorporeal Membrane Oxygenation (ECMO)

Total Artificial Hearts (TAHs)

Type

Implanted Heart Pump Devices

Extracorporeal Heart Pump Devices

End Use

Hospitals

Cardiac Centers

Research Institutes

Geography

North America

United States

Canada

Key Companies Covered (5 Viewpoints Each: Overview, Key Person, Recent Developments, SWOT, Revenue Analysis)

Abbott Inc.

Getinge AB

Teleflex Incorporated

Fresenius SE & Co. KGaA

LivaNova PLC

CorWave SA

Jarvik Heart Inc.

ABIOMED

Final Thoughts

The North America Heart Pump Device Market is on a transformative trajectory, powered by demographic shifts, technological breakthroughs, and expanding clinical acceptance. As the region becomes an epicenter of innovation in mechanical circulatory support, the market is poised for continued growth through 2033.

With device designs evolving toward greater safety, smaller size, and more intelligent monitoring, the next decade will redefine treatment standards for advanced heart failure patients across the United States and Canada.

Science

About the Creator

Sushant. Renub Research

I’m Sushanta Halder, Digital Marketing Manager at Renub Research with 15+ years in SEO, content, PPC & lead generation. Passionate about data-driven growth strategies.

Reader insights

Be the first to share your insights about this piece.

How does it work?

Add your insights

Comments

There are no comments for this story

Be the first to respond and start the conversation.

Sign in to comment

    Find us on social media

    Miscellaneous links

    • Explore
    • Contact
    • Privacy Policy
    • Terms of Use
    • Support

    © 2026 Creatd, Inc. All Rights Reserved.